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Abstract Human cells have numerous repair mechanisms
to counteract various insults incurred on the DNA. Any
mutation in these repair mechanisms can lead to accumu-
lation of DNA errors and carcinogenesis. This review aims
to discuss the therapeutic options in the two most common
DNA repair deficient cancer syndromes, namely Lynch
syndrome (hereditary non-polyposis colorectal cancer) and
breast cancer susceptibility gene (BRCA) associated
ovarian and breast cancer. Deficiency in DNA repair
mechanisms renders these tumors with increased sensitivity
to platinum agents. There has been increasing amount of
information on the utility of the defects in DNA repair as
targets for cancer therapy in these syndromes. Novel
therapies like poly (ADP-ribose) polymerase (PARP)
inhibitors are one of such example where the induction of
double stranded breaks in DNA leads to tumoricidal effect
in patients with homologous DNA repair deficiency.
Interestingly, patients with DNA repair deficiencies tend to
have a more favorable prognosis than sporadic malignan-
cies. In microsatellite high colorectal cancer patients, this
has been attributed to increased recruitment of CD8? T
lymphocytes in tumor microenvironment. However, these
tumors are able to limit the host immune response by
activation of immune checkpoints that seem like attractive
targets of therapy in the future.
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DNA repair mechanisms
Human cells are continuously exposed to countless insults,
ranging from ultravoilet light and ionizing radiation to the
use of alkylating and anti-tumor agents. In order to repair
the harmful DNA damages that ensue, the human body is
equipped with an intricate, interwoven damage control
network comprised of five DNA repair mechanisms: base
excision repair, mismatch repair, nucleotide excision
repair, homologous recombination and non-homologous
end-joining. Specifically, base excision repair is used to fix
single stranded breaks and small base changes. Mismatch
repair is used to correct A–G and T–C mismatches as well
as insertions and deletions. Nucleotide excision repair is
used to remove bulky adducts and intrastrand crosslinks.
Homologous recombination and non-homologous end
joining are used to fix double stranded breaks and remove
interstrand crosslinks. Mutations in the genetic makeup of
any of these mechanisms may result in defective DNA
repair, potentially leading to an abnormal pathology [1].
This review article will discuss the latest therapeutic
options in the major DNA repair deficient inherited cancer
syndromes, including hereditary non-polyposis colorectal
cancer (Lynch syndrome), and breast cancer susceptibility
gene (BRCA) associated ovarian and breast cancer.
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Lynch syndrome (hereditary non-polyposis
colorectal cancer)
DNA mismatch repair is a highly conserved mechanism
primarily used to correct mismatched base pairs that arise
as a result of replication errors or cellular damage [2]. It is
composed of four main genes—MLH1, MSH2, MSH6,
PMS2—that encode the mismatch repair (MMR) proteins
necessary for identification and repair of mismatched
bases. These proteins work in unison as two heterodimeric
complexes: MLH1/PMS2 and MSH2/MSH6 [3]. The genes
responsible for the stability of their respective hetero-
dimeric partners are MLH1 and MSH2 [4]. When a defect
in this proofreading system occurs, the loss of MMR pro-
tein results in an accumulation of errors within DNA
microsatellite regions. This phenomenon is known as
microsatellite instability (MSI) [5].
Deficient mismatch repair causing microsatellite insta-
bility is responsible for 12–15 % of all colorectal cancers.
Among this group, two-thirds are due to sporadic tran-
scriptional gene silencing while the remaining third is due
to a germline loss-of-function mutation [6]. In the sporadic
pathway, hypermethylation of CpG islands in the promoter
region causes MLH1 gene silencing to occur [2] (Fig. 1).
This is always accompanied by a BRAF V600E mutation
due to tight promoter correlation. Thus, MLH1 methylation
and tumor BRAF mutations are indicative of negative
DNA mismatch repair germline mutation status [7].
In contrast, deficient mismatch repair from a germline
loss-of-function mutation is associated with Lynch Syn-
drome, an autosomal dominant syndrome formerly known
as hereditary non-polyposis colorectal cancer. According to
the International Society for Gastrointestinal Hereditary
Tumors database, mutations in MLH1, MSH2, MSH6 and
PMS2 account for 42, 33, 18 and 7 % of Lynch syndrome,
respectively [8]. Pathology associated with Lynch Syn-
drome occurs only after a second hit, due to a somatic
event such as a point mutation or methylation, damages the
unaffected allele [3]. An alternative etiology for this syn-
drome is the germline epimutation of MLH1, a reversible
hypermethylation event that involves various normal tis-
sues [9]. In another subset of Lynch Syndrome patients,
constitutional, biallelic 30 exon deletion of the epithelial
cell adhesion molecule can cause epigenetic silencing of
the MSH2 gene and subsequent lack of MMR protein [10].
While cancer risks are elevated with the loss of any
MMR protein [11], the risks are stratified, as cancer risks
associated with MLH1 and MSH2 mutations are higher
than with MSH6 and PMS2 mutations [12, 13]. The tumor
spectrum in Lynch Syndrome is broad, with following
cancers listed in order of decreasing frequency: colorectal,
endometrial, gastric, biliopancreatic, and uroepithelial [14].
Deficient mismatch repair system
Sporadic transcriptional gene silencing:
MLH1 silencing
BRAF V600E mutation 
(66%)
Germline loss of function mutation
(hereditary non-polyposis CRC):








Fig. 1 Molecular pathways for
microsatellite instability (MSI)
high colorectal cancer. About
two-thirds of the cases are
sporadic and involve
transcriptional silencing of
MLH1 gene that is always
accompanied by a BRAF




function mutations in one of the
mismatch repair (MMR) genes
360 G. Goyal et al.
123
Thus, diligent screening is essential to decrease morbidity
and mortality of patients with Lynch Syndrome [9].
Despite the increased risk of cancer, high-frequency
microsatellite instability is associated with more favorable
outcomes in colorectal cancer, i.e. lower stage of cancer
and lower pathological stage [15] as well as a decreased
likelihood of metastasis [16]. Data published on the prog-
nosis of colorectal cancer in patients with a defect in
mismatch repair support the notion that this deficiency is a
positive prognostic factor in Stage II and III colorectal
carcinoma [17, 18]. It is also associated with a lower
recurrence rate of 11 % compared to 26 % in stage II and
III colorectal cancer with an intact repair system [19]. Due
to the inability to repair errors in DNA coding sequences,
an accumulation of somatic mutations occurs, leading to
the synthesis of neoantigens that are recognized by the
body’s own immune system [20]. The immunogenicity of
these neoantigens peptides creates a cytokine rich
microenvironment with a high density of tumor-infiltrating
lymphocytes, especially CD8? T lymphocytes, that per-
haps leads to the enhanced control over tumor growth and
spread [21, 22]. While the prevalence of advanced, meta-
static carcinoma is lower in mismatch repair deficient
individuals [16], prognosis is poor at this stage, with lower
disease free survival and overall survival than earlier stages
[23]. The prognostic impact of DNA mismatch repair
deficient individuals also depends on tumor site; proximal
tumors have favorable outcomes and distal or N2 tumors
correlate with worse outcomes [24].
Tumors with mismatch repair deficiency, are resistant to
therapy with 5-Fluorouracil alone [25, 26]. However,
available data suggests that mismatch repair deficient
tumors are sensitive to platinum agents like oxaliplatin or
FOLFOX (a combination of fluoropyrimidine, folic acid
and oxaliplatin), as the sensitivity is independent of the
repair system [27, 28]. The role of adjuvant FOLFOX in
MMR deficient colorectal cancer patients was demon-
strated by the long-term results from the MOSAIC (Mul-
ticenter International Study of Oxaliplatin/Fluorouracil/
Leucovorin in the Adjuvant Treatment of Colon Cancer)
study [29]. The study showed that MMR proficiency was
an independent poor prognostic factor in colorectal cancer
patients. However, the hazard ratio (HR) benefit for DFS
and OS in FOLFOX4 [bolus/infusional fluorouracil plus
leucovorin (LV5FU2) plus oxaliplatin] arm were 0.48
(95 % CI 0.20–1.12) and 0.41 (95 % CI 0.16–1.07),
respectively, for stage II and III MMR-deficient patients, as
compared to LV5FU2 arm [29]. This confirms a beneficial
role of using FOLFOX in patients with stage III dMMR
colorectal cancer.
Due to the resistance to 5-Fluorouracil, efforts are under-
way to identify novel therapies that exploit the DNA mis-
match repair deficiency in microsatellite unstable colorectal
cancers. A recent study conducted by Maby et al. [30] sug-
gests that CD8? tumor infiltrating lymphocyte density can be
positively correlated with the total number of frameshift
mutations, especially within the ASTE1, HNF1A and
TCF7L2 genes. Studies examining the tumor microenviron-
ment have shown that MSI tumors selectively increase the
upregulation of immune checkpoint ligands such as PD-1
(programmed cell death 1), CTLA-4 (cytotoxic T-lympho-
cyte-associated protein 4), LAG-3 (lymphocyte-activation
gene 3) and IDO (indoleamine 2,3-dioxygenase pathway),
thereby preventing natural elimination of the tumor [31].
These findings have inspired research to design novel
immunomodulatory therapy targeting this negative feedback
system.
There are currently two classes of immunomodulatory
monoclonal antibodies that are being developed to target
tumors- cytotoxic T-lymphocyte-associated protein 4
(CTLA-4) and programmed death-1 (PD-1) antibodies. The
anti CTLA-4 antibodies targets immunosuppressive
receptors on the surfaces of T lymphocytes to overcome the
effect of immune checkpoints [32]. The PD-1 inhibitors
block the interaction of PD-1 molecule with programmed
death-1 ligand (PD-L1) and facilitate tumor killing by
activated T cells [32]. Currently, three antibodies are
approved for oncological use: ipilimumab, nivolumab and
pembrolizumab. Ipilimumab, a CTLA-4 inhibitor, was
approved in 2011 for the treatment of metastatic mela-
noma. Nivolumab and pembrolizumab, programmed death-
1 (PD-1) inhibitors, were approved in 2014 for cases of
metastatic melanoma that progress on ipilimumab [32].
Currently, these agents have also been approved for use in
advanced non-small cell lung carcinoma (both nivolumab
and pembrolizumab) and renal cell carcinoma (nivolumab).
The adverse effect profile of the anti PD-1 drugs seems to
be less toxic than anti CTLA-4 antibody and includes
fatigue, pruritus and rash [32].
A recent phase 2 study conducted by Le et al. [33]
evaluated pembrolizumab in 41 patients with progressive
metastatic carcinoma with or without mismatch-repair
deficiency. Pembrolizumab was administered intra-
venously at a dose of 10 mg/kg every 2 weeks to both
colorectal (n = 32) and non-colorectal (n = 9) cancer
patients. All of the colorectal cancer patients except one
had received two or more previous chemotherapy regimens
and had similar duration of metastatic disease.
In the cohort with mismatch repair-deficient colorectal
cancer patients (n = 11), the immune-related objective
response rate (ORR) and immune-related progression free
survival (PFS) rate at 20 weeks with pembrolizumab was
40 and 78 %, respectively. On the other hand, the ORR and
PFS rate was 0 and 11 % for mismatch repair-proficient
colorectal cancers (n = 21), thereby suggesting a clinical
benefit with immune checkpoint blockade in patients with
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mismatch repair-deficient colorectal cancers [33].
Immunohistochemical analysis of the mismatch-repair
deficient tumors showed a higher density of CD8-positive
lymphoid cells and programmed death-1 ligand expression
(PD-L1) as compared to the mismatch-repair proficient
tumors. Of note, this study included a third cohort of
mismatch-repair deficient non-colorectal cancer patients
(n = 9) that showed an ORR of 71 % and 20-week PFS
rate of 67 % [33].
Current research is also targeting synthetic lethal inter-
actions of the mismatch repair pathway as well as sec-
ondary mutations [34]. Synthetic lethality between two
genes is the concept that loss of function in one of the
genes still produces a viable cell but loss of both genes
results in cell death [35]. With regards to the mismatch
repair pathway, there is evidence that inhibition of specific
DNA polymerases in the base excision repair pathway is
synthetically lethal with deficient mismatch repair proteins
[34]. Specifically, nuclear base excision repair DNA
polymerase ß is linked to MSH2 and mitochondrial DNA
polymerase ! is linked to MLH1 in such a manner that
inhibition of the polymerase can induce an accumulation of
oxidative DNA lesions in a mismatch repair deficient
tumor [36]. The use of methotrexate, a folate antimetabo-
lite, leads to selective accumulation of oxidative DNA
lesions in MSH2 deficient cells due to their inability to
clear the damage [37]. In light of this phenomenon, a phase
II clinical trial testing the cytotoxic effects of methotrexate
in MSH2 deficient colorectal cancer is underway (MESH,
NCT00952016) [34]. In addition to this, secondary muta-
tions are also a source that can be targeted. Studies have
shown that secondary mutations in double stranded base
repair genes are associated with primary mismatch repair
gene mutations [38]. With synthetic lethality between
double stranded base repair genes and poly (ADP-ribose)
polymerase (PARP), a base excision repair enzyme, ther-
apies combining methotrexate and a PARP inhibitor would
allow for the accumulation of oxidative stress in a mis-
match repair deficient tumor without the ability for DNA
repair [34, 39].
BRCA related ovarian cancer
BRCA 1 and BRCA 2 are two highly penetrant genes
crucial to DNA damage repair and genomic stability [40].
By participating in the repair of double stranded breaks,
they prevent the accumulation of gross chromosomal
rearrangements that would ultimately lead to tumor for-
mation [41]. BRCA1/2 proteins are particularly active
agents in the error-free homologous recombination repair
process [42, 43]. BRCA 1 is part of the BRCA1-associated
genome surveillance complex (BASC) involved in the
recognition and repair of aberrant DNA structures. The
complex interacts with the MRE1/RA50/Nbs1 complex to
reset double stranded break ends for homologous recom-
bination [44], complexes with SWI/SNF for chromatin
remodeling [45] and exhibits ubiquitin ligase activity [46].
BRCA 2 regulates RAD51 recombinase, a molecule that
initiates ssDNA pairing during homologous recombination
[47]. Inherited pathologic mutations in either BRCA genes
destabilize the genome, predisposing the individual to a
multitude of cancers.
Interestingly, BRCA-associated ovarian cancer has bet-
ter prognosis than sporadic ovarian carcinoma [40].
Genomic instability from BRCA mutations sensitizes
tumor cells to chemotherapeutic agents such as platinum
salts, decreasing the mortality rate by 28 % [48]. In addi-
tion, patients experience longer disease-free intervals after
primary chemotherapy as well as longer overall survival
[49]. A retrospective cohort study of 933 ovarian cancers
by Boyd et al. [49] showed that the group of BRCA-defi-
cient ovarian cancers (stage III and IV) had improved
survival and a longer disease-free interval following pri-
mary chemotherapy compared to the group of non-hered-
itary ovarian cancers. This phenomenon can be explained
by the heightened sensitivity to platinum gents associated
with the loss of BRCA proteins, conferring a greater
response to chemotherapeutic agents. In cumulative sur-
vival analysis by subtype of BRCA mutation, patients with
BRCA1 mutation had significantly longer survival than
sporadic cases (P = 0.008), but BRCA2- linked cases only
displayed a trend toward prolonger survival (P = 0.09).
One of the novel therapies entering phase II and III
clinical trials is a poly (ADP-ribose) polymerase (PARP)
inhibitor. PARP is an enzyme required for base excision
repair [50]. When activated by a single strand break, PARP
recruits DNA damage repair proteins to the site and facil-
itates the formation of a relaxed chromatin state to allow
for DNA repair [51]. The effects of PARP inhibition are
two-fold: single strand break repair complexes cannot be
recruited to the site and PARPs that are already recruited to
the site cannot undergo dissociation [52, 53]. This leads to
replication fork stalling and eventual collapse with for-
mation of double stranded DNA breaks [50, 53]. Without
the ability for high fidelity homologous recombination to
repair the breaks in BRCA mutant cases, an accumulation
of DNA damage occurs and cellular apoptosis ensues [50].
It is the discovery of synthetic lethality between PARP and
homologous recombination repair that has launched the use
of PARP inhibitors for the treatment of several cancers.
Currently, PARP inhibitors, such as olaparib, are under-
going clinical development to target a wide variety of cancer
types, including BRCA mutated breast and ovarian cancers
[54–57]. The United States Food and Administration has
also approved olaparib for use in BRCA-mutated ovarian
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cancers resistant to three prior chemotherapy regimens [58].
The current recommendation is treatment with 400 mg of
olaparib twice a day beginning no later than 8 weeks after
neoadjuvant platinum chemotherapy [59]. This was based on
a phase II trial of 193 patients with advanced ovarian cancer
who had a germline BRCA1/2 mutation. All of the patients
received prior therapy with platinum agents and were con-
sidered to be platinum resistant. Olaparib use was associated
with a tumor response rate of 31 %with a complete response
seen in 3 % of the cases. Partial responses were seen in 28 %
of the patients and stable disease C8 weeks was observed in
40 % of the patients with ovarian cancer. [59] Common side
effects of PARP inhibitors include fatigue, nausea, vomiting,
diarrhea, anorexia and dizziness. More serious adverse
effects include hematological toxicities, myelodysplastic
syndrome, acute myeloid leukemia and pneumonitis [60].
BRCA related breast cancer
While there is no standard chemotherapy regimen to treat
BRCA 1 or 2 mutated breast cancers, which are typically
high grade and triple negative in nature, clinical trials have
shown the superior efficacy of platinum salts as part of
neoadjuvant chemotherapy to shrink the tumor prior to
surgery [61]. Cisplatin and other platinum agents have the
ability to crosslink and damage DNA strands that can only
be repaired by high-fidelity homologous recombination
typically absent in BRCA mutated cells [62]. Without
BRCA proteins, there is a fivefold reduction in DNA
double-stranded break repair via homologous recombina-
tion [43]. BRCA-deficient cells have amplified radiation
sensitivity and a greater cellular response to ionizing
radiation [63], although one might hypothesize that this
might make them more susceptible to radiation induced
secondary malignancies.
A large observational study by Byrski et al. [64] esti-
mated the rates of pathologic complete response (pCR) for
various neoadjuvant chemotherapy regimens given to
young women with BRCA-1 positive breast cancers. Of the
102 women who carried a BRCA1 mutation, 24 patients
were able to reach pCR. Among the 12 patients that
received cisplatin, 83 % (n = 10) were able to achieve a
pCR. A pCR of 7 % was observed for those treated with
cyclophosphamide, methotrexate and fluorouracil (CMF),
8 % for those treated with doxorubicin and docetaxel (AT)
and 22 % for those treated with doxorubicin and
cyclophosphamide with and without fluorouracil (FAC,
AC) [64].
The same research group recently completed a study to
further evaluate the use of platinum-based neoadjuvant
chemotherapy for women with triple-negative, BRCA1
mutated breast cancer [65]. Cisplatin was administered at a
dose of 75 mg/m2 every 3 weeks for 4 cycles to 107
women diagnosed with stage I to III breast cancer, fol-
lowed by surgery and conventional chemotherapy. Ninety-
three of the patients had primary breast cancer and 14 of
the patients were previously treated for cancer. After cis-
platin chemotherapy, 65 out of the 107 patients (61 %) had
achieved pCR. Further analysis determined that the rate of
pCR was 56 % for women with ER-positive breast cancer,
61 % for those with triple-negative breast cancer, 73 % for
those with node-negative cancer and 48 % for those with
node-positive breast cancer. Since high pCR is suggestive
of greater recurrence-free survival, this data suggests that
platinum-based agents may be an effective neoadjuvant
chemotherapeutic option for women with BRCA-1 positive
breast cancer [65].
A recent randomized phase III trial by Tutt et al. eval-
uated the use of carboplatin compared with docetaxel in
376 patients with metastatic or recurrent locally advanced
triple negative or BRCA-mutated breast cancer. Patients
were randomized to either the carboplatin arm or the
docetaxel arm and were treated for 6–8 cycles or until
disease progression if sooner. At the conclusion of the
study, the objective response rate (ORR) for the 43 BRCA-
mutated breast cancer patients was 68.0 % with carboplatin
compared to 33.3 % with docetaxel (P = 0.03). There was
a no significant difference for non-BRCA patients, with an
ORR of 28.1 versus 36.6 % for carboplatin and docetaxel,
respectively (P = 0.16) [66].
Although platinum drugs are often used as monotherapy
in individuals with BRCA1 mutations, studies show that
combining platinum-based agents and conventional
chemotherapy can also achieve a high pathologic complete
response [67–69]. A recently published prospective study
demonstrated that neoadjuvant carboplatin/docetaxel
chemotherapy allowed for a pCR of 86 % in BRCA-as-
sociated triple negative breast cancers compared to a pCR
of 50 % in sporadic, non-BRCA associated triple negative
breast cancers [70]. Similarly, in another randomized phase
II trial, carboplatin with weekly paclitaxel/doxorubicin was
able to achieve a pCR of 53.2 %, compared to 36.7 %
without the carboplatin [67]. Despite the success of plat-
inum drugs, resistance to these agents have led to inno-
vative research to discover biologic agents that target other
repair mechanisms with synthetic lethality towards
homologous recombination.
A proof-of-concept phase II trial engineered by Tutt
et al. evaluated the use of olaparib in 54 patients with
confirmed recurrent, advanced BRCA1 or BRCA 2 muta-
ted breast cancer. Patients were either given continuous
oral olaparib at the maximum tolerated dose of 400 mg
twice daily (n = 27) or a low dose of 100 mg twice daily
(n = 27). This study revealed a therapeutic objective
response rate of 41 % in patients assigned to 400 mg twice
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daily compared to 22 % in patients assigned to 100 mg
twice daily [60]. Further, the combination of olaparib with
cisplatin has also proven efficacious, with a therapeutic
response rate of 73 % in BRCA related breast cancers [54].
Other combinations with PARP inhibitors include neoad-
juvant chemotherapy with carboplatin or topotecan [71–
73]. There also seems to be some synergistic activity
between veliparib, another PARP inhibitor, and temo-
zolomide, with a clinical benefit rate of 50 % [74]. Apart
from olaparib and veliparib, three other PARP inhibitors—
niraparib, talazoparib and rucaparib—are also undergoing
current investigation for use in advanced settings in
germline BRCA mutated breast cancer [75].
Hence we can see how the landscape of therapeutics in
DNA repair deficient cancer syndromes has evolved from
traditional chemotherapy towards targeted novel therapies
that aim to prolong survival with less toxicity. The use of
platinum agents in these syndromes has already led to
improved survival. With an increasing understanding of
DNA repair defects, the DNA damage repair (DDR) agent
olaparib is probably just a beginning of the utilization of
synthetic lethality in treatment of hereditary cancers.
Immune checkpoint inhibitors also seem to be a promis-
ing avenue in the management of hereditary cancers that
evade the immune system by limiting the cytotoxic T cell
response to these tumors. As more data becomes available
on genetic testing, we might be able to have more
information on expanding its scope to include other
malignancies. One might be tempted to hypothesize that
increased knowledge of DNA repair deficiencies could
perhaps open doors to the use of targeted therapy in
metastatic cancers of unknown primary that possess such
defects.
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